COST-EFFECTIVENESS ANALYSIS OF THE CORRECT VS IMPROPER USE OF RIVASTIGMINE TRANSDERMAL PATCH IN PATIENTS WITH ALZHEIMER'S DISEASE IN COLOMBIA

被引：0
|
作者：
Romero, M. [1 ]
Cuellar, K. [1 ]
Acero, G. [1 ]
Cuadros, R. [2 ]
Patino, A. [3 ]
机构：
[1] Grupo Proyectame, Bogota, DC, Colombia
[2] Asociac Colombiana Gerontol & Geriatria, Bogota, DC, Colombia
[3] Knight Therapeut Colombia, Bogota, DC, Colombia
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE116
引用
收藏
页码：S76 / S77
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
    Han, Hyun Jeong
    Lee, Jeong Ju
    Park, Sun A.
    Park, Hyun Young
    Kim, Jeong Eun
    Shim, Young Soo
    Shim, Dong-Seok
    Kim, Eun-Joo
    Yoon, Soo Jin
    Choi, Seong Hye
    JOURNAL OF CLINICAL NEUROLOGY, 2011, 7 (03): : 137 - 142
  • [32] COST-EFFECTIVENESS OF DONEPEZIL IN THE TREATMENT OF PATIENTS WITH ALZHEIMER'S DISEASE: AN UPDATE
    Chyr, L. C.
    Yapici, H. O.
    Padula, W., V
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [33] The cost-effectiveness of quetiapine for Alzheimer's disease in community dwelling patients
    Getsios, D
    Proskorovsky, I
    Caro, JJ
    O'Brien, J
    Pesa, J
    Ward, AJ
    VALUE IN HEALTH, 2005, 8 (03) : 315 - 315
  • [34] The cost-effectiveness of a behavior intervention with caregivers of patients with Alzheimer's disease
    Nichols, Linda O.
    Chang, Cyril
    Lummus, Allan
    Burns, Robert
    Martindale-Adams, Jennifer
    Graney, Marshall J.
    Coon, David W.
    Czaja, Sara
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (03) : 413 - 420
  • [35] Effects of Rivastigmine Transdermal Patch and Capsule on Aspects of Clinical Global Impression of Change in Alzheimer's Disease: A Retrospective Analysis
    Cummings, Jeffrey L.
    Ferris, Steven H.
    Farlow, Martin R.
    Olin, Jason T.
    Meng, Xiangyi
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2010, 29 (05) : 406 - 412
  • [36] Health utilities in Alzheimer’s disease and implications for cost-effectiveness analysis
    Peter J. Neumann
    PharmacoEconomics, 2005, 23 : 537 - 541
  • [37] Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis
    Neumann, PJ
    PHARMACOECONOMICS, 2005, 23 (06) : 537 - 541
  • [38] Visual Hallucinations Due to Rivastigmine Transdermal Patch Application in Alzheimer's Disease; The First Case Report
    Degirmenci, Yildiz
    Kececi, Hulusi
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2016, 10 (04) : 240 - 241
  • [39] Modeling cost-effectiveness of pharmaceuticals in Alzheimer's disease
    Oremus, Mark
    Tarride, Jean-Eric
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (03) : 275 - 277
  • [40] Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine
    Hauber, AB
    Gnanasakthy, A
    Mauskopf, JA
    CLINICAL THERAPEUTICS, 2000, 22 (04) : 439 - 451
12345